Piper Sandler analyst Jessica Tassan raised the firm’s price target on Tabula Rasa HealthCare to $6 from $4 and keeps a Neutral rating on the shares. The company reported "solid" Q4 results but its gross margin trends "present a significant and underappreciated headwind," the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TRHC:
- Tabula Rasa HealthCare sees FY23 revenue $343M-$354M, consensus $337.9M
- Tabula Rasa HealthCare sees Q1 revenue $82M-$84M, consensus $76.27M
- Tabula Rasa HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results
- Tabula Rasa HealthCare reports Q4 revenue $82.7M, consensus $81.39M
- Medication Management Services Leader Cureatr Acquires SinfoníaRx